OncoLize: “Treating Tumors from the Inside” OncoLize (Leiden, NL) develops injectable drug depots for localized, intra-tumoral drug delivery. The company is preparing its IND and CT Phase I/II for pancreatic cancer and other indications by end of 2024. Delivering generic chemo or novel drugs this way offers precision: 10-100x higher concentration at target, much smaller doses and up to 1000x lower drug levels outside the tumor… Improved outcome, far less side effects and affordable. The highly experienced team closed a Seed round of €1,6 million in April and expects to raise a Series A €8-12 mln by end of 2024 to achieve CT phase I/II studies in up to 3 indications.